+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sexually Transmitted Diseases Diagnostics Market - Global Forecast to 2030- Product Image
Sexually Transmitted Diseases Diagnostics Market - Global Forecast to 2030- Product Image
Sale

Sexually Transmitted Diseases Diagnostics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055581
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sexually Transmitted Diseases Diagnostics Market grew from USD 12.78 billion in 2024 to USD 13.53 billion in 2025. It is expected to continue growing at a CAGR of 6.03%, reaching USD 18.17 billion by 2030.

The global landscape of sexually transmitted disease (STD) diagnostics has undergone a dramatic transformation in recent years, driven by escalating infection rates, technological breakthroughs, and shifting patient expectations. Rising prevalence of infections such as chlamydia, gonorrhea, herpes simplex virus (HSV), human immunodeficiency virus (HIV), human papillomavirus (HPV), and syphilis has placed unprecedented pressure on public health systems and clinical laboratories alike. Consequently, healthcare stakeholders are demanding faster, more accurate, and cost-effective testing solutions that can keep pace with evolving epidemiological trends.

Innovations in molecular diagnostics, the proliferation of point-of-care and at-home testing kits, and the integration of digital health platforms have collectively redefined diagnostic workflows. In parallel, regulatory bodies in key markets are updating guidelines to accommodate novel technologies, ensuring stringent quality standards while expediting market access. Against this backdrop, decision-makers must navigate a rapidly shifting terrain where agility, strategic partnerships, and data-driven insights are paramount. This executive summary provides a concise yet thorough overview of the pivotal shifts, segmentation nuances, regional dynamics, competitive landscape, and actionable strategies that industry leaders must embrace to thrive in the evolving STD diagnostics arena.

Transformative Shifts Redefining STD Diagnostics

Over the last five years, the STD diagnostics field has experienced several transformative inflection points that have reshaped testing paradigms. First, molecular assays based on nucleic acid amplification techniques have become the gold standard for accuracy and sensitivity, driving laboratories to phase out older serological methods. Second, the democratization of diagnostics through point-of-care platforms and at-home test kits has empowered patients to take charge of their sexual health, reducing barriers to screening and increasing early detection rates. Moreover, telehealth integration now allows seamless remote consultations coupled with digital result reporting, optimizing patient engagement and care continuity.

Regulatory agencies have also adapted to these innovations, introducing accelerated review pathways for breakthrough diagnostic technologies and harmonizing international standards to facilitate cross-border approvals. In addition, data analytics and artificial intelligence solutions are being embedded into diagnostic workflows to enhance predictive capabilities, streamline laboratory operations, and preempt supply-chain disruptions. Taken together, these converging trends are not only broadening access to testing but also elevating the overall quality and timeliness of diagnostic insights.

Cumulative Impact of New U.S. Tariffs on Diagnostics

The introduction of new tariff measures by the United States government in early 2025 has exerted a significant cumulative impact on the supply chain dynamics and cost structure for STD diagnostic products. Many core reagents, assay components, and instrument parts sourced from leading international suppliers have become subject to increased import duties, leading manufacturers to reassess their global procurement strategies. Consequently, production costs for nucleic acid amplification tests, enzyme-linked immunosorbent assays, and rapid plasma reagin kits have risen, exerting upward pressure on end-user pricing.

In response, several diagnostic firms have initiated dual strategies that include reshoring critical manufacturing processes to domestic facilities and diversifying vendor portfolios to mitigate single-source dependencies. Furthermore, collaborative partnerships with downstream distributors have been renegotiated to share tariff burdens and preserve competitive pricing. On the policy front, industry associations are engaging with regulatory bodies to secure tariff exemptions for essential public health diagnostics. These collective efforts underscore the importance of proactive supply-chain resilience and financial agility in an era of shifting trade policies.

Key Segmentation Insights Across the Diagnostics Spectrum

The market exhibits pronounced variability across multiple segmentation dimensions, each reflecting unique clinical and commercial drivers. When examining disease type, Chlamydia and Gonorrhea remain highly prevalent, yet advanced molecular assays for Herpes Simplex Virus and Human Papillomavirus are gaining traction due to growing awareness of long-term health implications. In the realm of test types, laboratory testing continues to dominate through established platforms such as Enzyme-Linked Immunosorbent Assay, Nucleic Acid Amplification Tests, and the widely used Rapid Plasma Reagin assay, while point-of-care testing is experiencing robust uptake as home testing kits and rapid tests deliver immediate, user-friendly results.

Sample type also plays a critical role: blood-based assays provide comprehensive serological profiling, urine specimens offer non-invasive convenience for Chlamydia and Gonorrhea screening, and vaginal swabs optimize detection rates for HPV and HSV. From the end-user perspective, hospitals and clinics represent cornerstone customers, yet homecare settings and decentralized point-of-care environments are emerging as vital channels for expanding screening outreach. Public health laboratories and research laboratories continue to drive large-scale surveillance and novel assay validation. Finally, distribution channels bifurcate between direct sales agreements that ensure deep customer engagement and distributor networks that extend geographic reach.

Key Regional Insights Shaping Market Dynamics

Regional dynamics in the STD diagnostics market reveal distinct adoption patterns and regulatory environments. In the Americas, a robust healthcare infrastructure combined with proactive public health initiatives has accelerated uptake of molecular and rapid diagnostic platforms. Government funding and reimbursement policies in North America, in particular, continue to incentivize comprehensive screening programs. Shifting focus toward decentralized testing in Latin America is driven by efforts to improve rural access and curb infection rates through community-based interventions.

The Europe, Middle East & Africa region presents a mosaic of markets at varying maturity levels. Western Europe leads with stringent quality standards and reimbursement frameworks that favor innovative assays, while emerging economies in Eastern Europe and select Middle Eastern countries are investing in modernizing laboratory networks. In Africa, donor-funded programs and public-private partnerships are catalyzing the rollout of point-of-care and mobile testing initiatives to address high disease burdens.

In the Asia-Pacific, rapid urbanization and growing healthcare expenditures are propelling demand for both centralized and decentralized diagnostics. Regulatory harmonization efforts across major markets such as China, India, Japan, and Australia have lowered entry barriers for new technologies. Additionally, domestic manufacturers are scaling up capacity to serve regional needs, creating a competitive environment that fosters innovation and price optimization.

Competitive Landscape and Leading Player Strategies

The competitive landscape is characterized by a balance between established industry titans and agile innovators. Abbott Laboratories continues to fortify its leadership with a broad assay portfolio spanning HIV, HPV, and multiplex STD panels, while Astra Biotech GmbH focuses on bespoke point-of-care solutions tailored to niche markets. Becton Dickinson and company leverages its distribution prowess to integrate molecular and rapid testing platforms, whereas Bio-Rad Laboratories, Inc. deepens its research-grade assay offerings for clinical and public health laboratories.

bioMérieux SA and Danaher Corporation both invest heavily in R&D to expand molecular diagnostics capabilities, with Danaher’s recent acquisitions enhancing its reach in home testing. Daye Limited and Diasorin S.p.A differentiate through innovative sample preparation technologies that streamline workflow efficiency. F. Hoffmann-La Roche Ltd. sustains its position via high-throughput systems and strategic partnerships with academic institutions. Geneproof, Hologic Inc., and Jiangsu BioPerfectus Technologies Co., Ltd drive cost-effective NAAT solutions, while Liferiver Bio-Tech Corp. and MedMira Inc. pioneer multiplex and point-of-care immunoassays.

Merck KGaA and Meridian Bioscience Inc. offer complementary antigen and antibody testing kits, and Mylab Discovery Solutions Pvt. Ltd. capitalizes on the surging demand for domestic production in emerging markets. Novartis AG and OraSure Technologies, Inc. exploit cross-portfolio synergies to deliver combined oral fluid and blood-based tests. Qiagen Inc., Quest Consumer Inc., and Sansure Biotech Inc. each harness digital reporting tools to enhance patient engagement, while Seegene Inc. and Siemens Healthineers AG emphasize assay automation and throughput. Thermo Fisher Scientific, Inc. rounds out the landscape with scalable instrument platforms and comprehensive reagent ecosystems.

Actionable Recommendations for Industry Leadership

To navigate the evolving STD diagnostics environment and secure sustainable growth, industry leaders should:
  • Strengthen supply-chain resilience by diversifying suppliers, localizing critical manufacturing, and establishing strategic inventory buffers.
  • Accelerate adoption of integrated digital health solutions that combine remote consultation, test ordering, and automated result reporting to enhance patient experience and data capture.
  • Expand point-of-care and at-home testing portfolios to address unmet demand in decentralized settings and align with consumer preferences for convenience and privacy.
  • Forge cross-sector partnerships with public health agencies, technology vendors, and academic institutions to co-develop next-generation molecular assays and AI-driven analytics.
  • Align regional go-to-market strategies with local reimbursement frameworks, regulatory requirements, and cultural nuances to achieve optimal market penetration.
  • Invest in continuous quality improvement and clinical validation studies to uphold diagnostic accuracy while meeting evolving regulatory standards.
  • Monitor tariff and trade policy developments proactively, leveraging industry coalitions to advocate for tariff exemptions on essential diagnostic supplies and minimize cost volatility.

Conclusion: Seizing Opportunities in STD Diagnostics

The STD diagnostics sector stands at a pivotal juncture where technological innovation, shifting trade policies, and evolving care models converge. By embracing advanced molecular platforms, amplifying decentralized testing options, and integrating digital health ecosystems, stakeholders can enhance diagnostic precision, patient engagement, and operational efficiency. Navigating tariff-induced cost pressures demands proactive supply-chain diversification and strategic advocacy to secure critical components at stable prices. Tailored regional strategies, underscored by local regulatory alignment and partnership ecosystems, will prove instrumental in driving adoption across diverse markets. Finally, fostering collaborations between established players and emerging innovators will accelerate the development of next-generation assays, ensuring that public health objectives keep pace with epidemiological challenges. Through these concerted efforts, the industry can unlock new avenues for growth while fulfilling its mandate to improve sexual health outcomes globally.

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Diseases Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Chlamydia
  • Gonorrhea
  • Herpes Simplex Virus (HSV)
  • Human Immunodeficiency Virus (HIV)
  • Human Papillomavirus (HPV)
  • Syphilis
  • Laboratory Testing
    • Enzyme-linked Immunosorbent Assay (ELISA)
    • Nucleic Acid Amplification Tests (NAATs)
    • Rapid Plasma Reagin (RPR)
  • Point-of-Care Testing
    • Home Testing Kits
    • Rapid Tests
  • Blood
  • Urine
  • Vaginal Swabs
  • Homecare Settings
  • Hospitals & Clinics
  • Point-of-Care Settings
  • Public Health Labs
  • Research Laboratories
  • Direct Sales
  • Distributors

This research report categorizes the Sexually Transmitted Diseases Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Sexually Transmitted Diseases Diagnostics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Astra Biotech GmbH
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc.
  • Merck KGaA
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Qiagen Inc.
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sexually Transmitted Diseases Diagnostics Market, by Disease Type
8.1. Introduction
8.2. Chlamydia
8.3. Gonorrhea
8.4. Herpes Simplex Virus (HSV)
8.5. Human Immunodeficiency Virus (HIV)
8.6. Human Papillomavirus (HPV)
8.7. Syphilis
9. Sexually Transmitted Diseases Diagnostics Market, by Test Types
9.1. Introduction
9.2. Laboratory Testing
9.2.1. Enzyme-linked Immunosorbent Assay (ELISA)
9.2.2. Nucleic Acid Amplification Tests (NAATs)
9.2.3. Rapid Plasma Reagin (RPR)
9.3. Point-of-Care Testing
9.3.1. Home Testing Kits
9.3.2. Rapid Tests
10. Sexually Transmitted Diseases Diagnostics Market, by Sample Type
10.1. Introduction
10.2. Blood
10.3. Urine
10.4. Vaginal Swabs
11. Sexually Transmitted Diseases Diagnostics Market, by End-User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals & Clinics
11.4. Point-of-Care Settings
11.5. Public Health Labs
11.6. Research Laboratories
12. Sexually Transmitted Diseases Diagnostics Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Distributors
13. Americas Sexually Transmitted Diseases Diagnostics Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Sexually Transmitted Diseases Diagnostics Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Sexually Transmitted Diseases Diagnostics Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Astra Biotech GmbH
16.3.3. Becton Dickinson and company
16.3.4. Bio-Rad Laboratories, Inc.
16.3.5. bioMérieux SA
16.3.6. Danaher Corporation
16.3.7. Daye Limited
16.3.8. Diasorin S.p.A
16.3.9. F. Hoffmann-La Roche Ltd.
16.3.10. Geneproof
16.3.11. Hologic Inc.
16.3.12. Jiangsu BioPerfectus Technologies Co., Ltd
16.3.13. Liferiver Bio-Tech Corp.
16.3.14. MedMira Inc.
16.3.15. Merck KGaA
16.3.16. Meridian Bioscience Inc.
16.3.17. Mylab Discovery Solutions Pvt. Ltd.
16.3.18. Novartis AG
16.3.19. OraSure Technologies, Inc.
16.3.20. Qiagen Inc.
16.3.21. Quest Consumer Inc.
16.3.22. Sansure Biotech Inc.
16.3.23. Seegene Inc.
16.3.24. Siemens Healthineers AG
16.3.25. Thermo Fisher Scientific, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID PLASMA REAGIN (RPR), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY VAGINAL SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 97. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 98. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 99. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 100. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 104. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 105. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 106. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 107. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 118. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 119. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 120. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 121. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 160. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 161. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 162. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 163. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 180. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 182. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 183. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 184. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 189. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 190. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 191. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 196. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 197. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 198. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 203. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 204. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 205. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 206. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 210. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 211. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 212. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 223. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 224. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 225. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 226. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 227. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 244. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 245. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 246. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 247. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 251. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 252. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 253. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 254. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 255. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 259. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 260. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 261. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 262. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA SEXUALLY TRANSMITTED D

Companies Mentioned

  • Abbott Laboratories
  • Astra Biotech GmbH
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc.
  • Merck KGaA
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Qiagen Inc.
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sexually Transmitted Disease Diagnostics Market - Global Forecast to 2030 - Product Image

Sexually Transmitted Disease Diagnostics Market - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Sexually Transmitted Disease Diagnostics Market Report by Type, Device Type, End User, and Region 2025-2033 - Product Image

Sexually Transmitted Disease Diagnostics Market Report by Type, Device Type, End User, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
Sexually Transmitted Diseases (STDs) Drug - Global Strategic Business Report - Product Image

Sexually Transmitted Diseases (STDs) Drug - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Sexually Transmitted Disease Test Market

The Sexually Transmitted Disease (STD) Test market is a subset of the Diagnostics industry. STD tests are used to detect the presence of a sexually transmitted infection, such as chlamydia, gonorrhea, syphilis, and HIV. These tests are typically conducted in a laboratory setting, and may involve a physical examination, a blood test, or a urine test. The results of these tests can help diagnose and treat an infection, as well as prevent the spread of the disease. The STD Test market is driven by the increasing prevalence of STDs, as well as the need for early detection and treatment. Additionally, the availability of rapid testing technologies has made STD testing more accessible and affordable. Some companies in the STD Test market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.